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Background: Appetite disorders are frequent and scantly studied in peritoneal dialysis
(PD) patients and are associated with malnutrition and cardiovascular complications.
Objective: We investigated the relationship between uremic insulin resistance, pro-
inflammatory cytokines, and appetite-related peptides release (ARPr) with eating-
behavior disorders in PD patients.
Methods: We included 42 PD patients (12 suffering anorexia, 12 obese with high
food-intake, and 18 asymptomatic) and 10 controls. We measured blood levels of
ARPr including orexigens [neuropeptide-Y (NPY), ghrelin, and nitric-oxide], anorexigens
[cholecystokinin, insulin, corticotropin-releasing factor, leptin, and adiponectin (Ad)], and
cytokines (TNF-α, sTNFα-R2, and IL-6) both at baseline and after administering a
standard-food stimulus (SFS). We also measured the expression of TNF-α, leptin and
Ad-encoding mRNAs in abdominal adipose tissue. We compared these markers with
eating motivation measured by a Visual Analog Scale (VAS).
Results: Anorexics showed both little appetite, measured by a VAS, and low levels of
orexigens that remained constant after SFS, coupled with high levels of anorexigens
at baseline and after SFS. Obeses showed higher appetite, increased baseline levels
of orexigens, lower baseline levels of anorexigens and cytokines and two peaks of
NPY after SFS. The different patterns of ARPr and cytokines pointed to a close
relationship with uremic insulin resistance. In fact, the euglycemic–hyperglycemic clamp
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reproduced these disorders. In anorexics, TNF-α fat expression was increased. In obese
patients, leptin expression in fat tissue was down-regulated and showed correlation
with the appetite.
Conclusion: In PD, appetite is governed by substances that are altered at baseline
and abnormally released. Such modulators are controlled by insulin metabolism and
cytokines and, while anorexics display inflammatory predominance, obese patients
predominantly display insulin resistance.
Keywords: appetite peptides, pro-inflammatory cytokines, insulin resistance, fat tissue gene expression,
peritoneal dialysis, euglycemic–hyperglycemic clamp
INTRODUCTION
Malnutrition is a severe and frequent (20–40%) complication
in peritoneal dialysis (PD) patients. Its cause is not entirely
known but it has been associated with the accumulation of pro-
inflammatory cytokines, as well as metabolic and eating behavior
disorders (EBD) (Owen et al., 1999). EBD in PD patients may
range from anorexia to obesity with high food intake. Anorexia
is the main obstacle to achieve an adequate nutritional status,
while obesity is frequently associated with protein malnutrition,
inducing a Kwashiorkor-like syndrome (Aguilera et al., 2004b).
In renal patients there is an accumulation in plasma of uremic
toxins., PD is an essential daily life-saving treatment for end-stage
renal failure and involves the exchange of solutes and the excess
of water between blood and dialysis solution across the peritoneal
membrane, which results in gradual reduction of uremic solutes
and toxins (Raby and Labéta, 2018; Nigam and Bush, 2019).
Reduced appetite (anorexia) is an early and usual symptom of
uremic syndrome (Carrero et al., 2007, 2008). Anorexia in dialysis
patients has been historically considered as a sign of uremia due
to “inadequate” dialysis. Additionally the inflammation may also
play a role in the genesis of appetite disorders in these patients
(Aguilera et al., 2004b; Chazot, 2009).
Appetite is regulated by numerous organs, including the
liver, the gastrointestinal tract (GIT) and the brain. The
hypothalamus, is the main regulating region of the brain for
appetite and energy homeostasis, involving counter-regulation
of appetite by orexigenic molecules, including neuropeptide-
Y (NPY), ghrelin and nitric-oxide and anorexigenic molecules,
such as proopiomelanocortin (POMC), cholecystokinin (CCK),
insulin, corticotropin-releasing factor (CRF), leptin, adiponectin
(Ad), and pro-inflammatory cytokines (Yu and Kim, 2012).
It has been shown that low NPY serum levels are associated
with anorexia in PD patients (Aguilera et al., 1998, 2004a; Yu
and Kim, 2012). NPY is a 36-amino acid peptide and is the most
abundant and widely distributed neuropeptide in the human
brain (Adrian et al., 1983). In the periphery, NPY is expressed
primarily in sympathetic ganglia, the adrenal medulla, and in
platelets (Larhammar, 2001; Hirsch and Zukowska, 2012). The
main effects of NPY are increased food intake and decreased
physical activity. It also increases the proportion of energy stored
as fat and blocks nociceptive signals to the brain. In regards of
its role in obesity, it has been shown that an increase in NPY
is caused by high levels of glucocorticosteroids through directly
activating type II glucocorticosteroids receptors and indirectly,
by abolishing the negative feedback of CRF on NPY synthesis and
release (Brothers and Wahlestedt, 2010).
Corticotropin-releasing factor is a 41-aa neuropeptide
secreted by neurons in the paraventricular nucleus of the
hypothalamus (Vale et al., 1981), this has a role in the regulation
of ACTH release and also the major physiological regulator of the
hypothalamic–pituitary–adrenal (HPA) axis (Smagin et al., 2001;
Sabzevari et al., 2019), and has an important role in the control
of food intake (Tanaka et al., 2009). CRF has been measured in
peripheral plasma in several diseases, stress situations, and HPA
disorders and it has been suggested that the major proportion
of plasma CRF has a hypothalamic origin (Suda et al., 1985;
Cunnah et al., 1987; Ellis et al., 1990; Wittert et al., 1991; Donald
et al., 1994; Catalán et al., 1998).
The pathogenesis of the wide spectrum of appetite disorders
in uremia is unknown. The accumulation of appetite-related
peptides (ARPs) and pro-inflammatory cytokines (Aguilera et al.,
1993) upon renal failure may alter the hunger-satiety cycle. Both
ARPs and cytokines might interact and potentiating each other,
producing a wide range of eating behavior responses. In this
context, it has been shown that CCK and interleukin-1 (IL-1) may
synergize to worsen anorexia and that TNF-α may interfere with
the orexigenic effect of neuropeptide-Y (NPY) (Xu et al., 1988;
Daun and McCarthy, 1993).
Given the proposed definition of “malnutrition, inflammation,
and atherosclerosis” (MIA) syndrome, dialysis patients may
suffer from two types of malnutrition: Type-I malnutrition,
in reference to a severe form of cachexia due to high plasma
levels of inflammatory mediators that produce systemic catabolic
effects, being anorexia one of the most important symptoms; and
Type-II malnutrition, that is usually mild and reversible, and that
is barely mediated by inflammation (Stenvinkel et al., 2000).
The other important groups of features that regulate appetite
are associated with glucose and insulin metabolism (Isganaitis
and Lustig, 2005). It is well known that uremic state is
associated with insulin resistance (Zoccali et al., 2005) and a
clear relationship between insulin release, glucose metabolism,
ARP-release (ARPr) and pro-inflammatory cytokines has been
established (Kalra et al., 2008). IL-1 and TNF-α induce insulin
resistance and the sense of satiety that acts on the hypothalamus
(central anorexia) (Isganaitis and Lustig, 2005). Some ARP
and cytokines retained during renal failure contribute to the
perpetuation of insulin resistance and to the establishment of
Frontiers in Physiology | www.frontiersin.org 2 May 2019 | Volume 10 | Article 630
fphys-10-00630 May 28, 2019 Time: 12:1 # 3
Avila-Carrasco et al. Disturbances in Appetite Modulators in PD Patients
chronic appetite disorders (Aguilera et al., 2004a; Zoccali et al.,
2005). In this sense, fat tissue plays a crucial role in insulin
metabolism, controlling the release of peptides and cytokines
(Isganaitis and Lustig, 2005; Axelsson, 2008). The abnormalities
in leptin, Ad or resistin fat gene expression indicate that the
influence of fat tissue on such metabolism is particularly affected
by uremia (Kalra et al., 2008).
We were interested in defining the relationship between ARPr,
circulating cytokines, insulin resistance, fat gene expression and
EBD in PD patients. This population is of particular interest,
since PD patients are exposed to constant peritoneal glucose
absorption, which may worsen disorders of glucose metabolism
and directly induce central anorexia (Aguilera et al., 2004b;
Kalra et al., 2008). In some cases, the tendency toward high
plasma levels of anorexigen peptides is thought to reflect the
disequilibrium between orexigens and anorexigens (Aguilera
et al., 2004b). However, not all PD patients suffer anorexia
under similar conditions, suggesting that factors like peritoneal
glucose absorption and insulin metabolism, or dialysis clearance,
influence on appetite control. Accordingly, we hypothesize that
disturbances in the secretion and/or renal retention of ARP and
inflammatory cytokines, all of which act on fat tissue and are
associated with insulin resistance, induce different EBD, ranging
from anorexia to obesity with high food intake.
MATERIALS AND METHODS
We included 42 clinically stable PD patients (20 males and
22 females), 20 with continuous ambulatory peritoneal dialysis
(CAPD) and 22 with automated PD. The causes of chronic renal
failure were nephrosclerosis in 15 patients, glomerulonephritis
in 11, polycystic kidney disease in 8, systemic disease in 4 and
unknown in 4. Of these 42 PD patients: 12 suffered anorexia,
12 were obese with high food-intake and 18 were asymptomatic.
We excluded diabetic patients, and those suffering from
neoplasias, chronic or acute infections, liver, and rheumatoid
diseases. We also included 10 healthy controls. This research was
carried out in accordance with Good Clinical Practice Guidelines,
applicable regulations as well as the ethical principles that have
their origin in the Declaration of Helsinki. All of included
patients signed a written consent.
Dialysis Adequacy and
Nutritional Markers
Urea-Kt/V and nPNA (normalized protein nitrogen appearance)
were calculated by standard methods (Selgas et al., 1993).
Long-term nutritional markers in plasma/serum were analyzed:
creatinine, albumin, cholesterol (colorimetric method, Hitachi
704) and transferrin were assayed by immunonephelometric
methods (Boering Nephelometric-Terminal S.A., Spain)
and serum iron (Hitachi 911). Medium-term nutritional
markers were also assessed, plasma prealbumin and retinol-
binding protein (RBP) immunonephelometric method). Serum
growth hormone (GH) was determined by ELISA (AIA 1200;
Tosoh Corporation, Tokyo, Japan), normal value <5 ng/mL.
Serum IGF-I was determined by radioimmunoassay, RIA
(Nichols Institute Diagnostics, San Juan Capistrano, CA,
United States), normal range between 83 and 450 ng/mL. The
short-term nutritional markers analyzed in serum were: urea
nitrogen, phosphate, and potassium. The mean daily dietary
intake was determined from the individual 24-h food records
over a 3-day period (Food composition tables, Wander-Sandoz
Nutrition, Barcelona, Spain; Jiménez Cruz et al., 1990).
Anthropometric parameters explored were: triceps skin-fold
(TSF), mid-arm circumference (MAC), and mid-arm muscle
circumference [MAMC (cm) = MAC (cm) – 3.14 × TSF (cm)].
The TSF was determined using a caliper (Holtain Ltd., Cross-
well, Crymych, Dyfed, United Kingdom). Body composition was
determined through bioelectric impedance (BI: multi-frequency,
Maltron BF 905, United States).
Eating Motivation Analysis
To evaluate eating motivation in the patients, we use Visual
Analog Scale (VAS), which includes five questions. The results
were given in a horizontal scale (0–100) (Hylander et al., 1997).
Anorexia was defined by three criteria: low eating motivation
measured by VAS, that was considered when the mean of all
answers was <60; low food intake (nPNA < 1.1 g/kg/day and
daily dietary assessment <35 kcal/kg/day); and low nutritional
markers (according to KDOQI clinical practice guideline of
nutrition) (Kopple, 2001; Aguilera et al., 2004b).
Obesity with high food intake was considered when the BMI
was higher than 30 kg/m2, and eating motivation (VAS) and daily
food intake was high (Hylander et al., 1997).
According to body composition, nutritional status, eating
motivation and the knowledge derived from eating behavior
disorders studied in other medical areas (Robins et al., 1988;
American Psychiatric Association, 2013), we divided our patients
into three groups: suffering anorexia (n = 12), obesity (n = 12)
with high food intake or without EBD (n = 18). Finally, we
included a control group of 10 health volunteers.
We evaluate the appetite peptide modulators at the baseline
(fasting condition), as well as 30, 60, and 90 min after
the ingestion of a standard 750 mL nutritional supplement
(FresubinTM, Fresenius, Medical Care, Germany). They were
analyzed according to manufacturer recommendation. These
peptides included:
Hormones and Peptides Related to
Insulin Resistance
(1) Glucose: assayed by the hexokinase reaction
(Boehringer Mannheim, Germany). The normal
fasting range from 90 to 120 mg/dL.
(2) Insulin (Sorin; Biomedica, Saluggia, Italy): normal
range 10–15 µU/mL.
(3) C-peptide (Medigenix; Diagnostics Fleurus, Belgium):
normal range 0.5–3 ng/mL.
(4) Glucagon (ICN Biomedicals, Irvine, CA, United States):
normal range 70–90 pg/mL.
(5) Gastric inhibitory peptide (GIP; ELISA, Peninsula
Laboratories, Inc., Belmont, CA, United States): normal
range 35–52 pg/mL.
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Insulin Resistance (IR) Test
(1) Insulin resistance (IR) was estimated using the
homeostatic model assessment (HOMA-IR).
HOMA-IR = Fasting insulin (µU/mL) × fasting
glucose (mg/dL)/405. Low-IR values indicate high
insulin sensitivity, whereas high-HOMA values
indicate low insulin sensitivity (insulin resistance)
(Matthews et al., 1985).
(2) Euglycemic hyperinsulinemic clamp studies were
performed to discriminate the effect of hyperglycemia
and hyperinsulinemia separately on ARPr. We followed
the methodology of DeFronzo et al. (1979).
Anorexigenic Peptides
(1) Cholecystokinin, the 26–33 unsulfated fragment
(ELISA, Peninsula Laboratories, Inc., Belmont, CA,
United States): normal values 12–20 pg/mL.
(2) Leptin (RIA, Linco Research, St. Louis, MO,
United States): normal range 3–7.8 ng/mL.
(3) Adiponectin (Ad; RIA, Linco Research, St. Charles, MO,
United States): normal values in our population were
25–33 µg/mL.
(4) Corticotropin-releasing factor (CRF; ELISA, Easia
Medigenix Diagnostics S.A., Belgium): normal
range 20–40 pg/mL.
Orexigenic Peptides
(1) Neuropeptide Y (NPY; ELISA, Peninsula Laboratories,
Inc., Belmont, CA, United States): normal range
220–370 pg/mL.
(2) Nitric oxide (NO) measured as serum nitrate NO3,
a final metabolite of NO, by capillary electrophoresis:
normal range in 109 healthy volunteers was between 90
and 110 µmol/L.
(3) Ghrelin, the 125I-Ghrelin (RIA, Linco Research,
St. Charles, MO, United States): normal range
900–2,500 pg/mL.
Cytokines Acting on Appetite Control
(1) Tumor necrosis factor (TNF-α) and IL-1, were
determined by ELISA (Easia Medigenix, Diagnostics
S.A., Belgium), normal ranges were 3–20 pg/mL and
1–16 pg/mL, respectively.
(2) IL-6 (R&D Systems, Minneapolis, MN, United States:
normal range 0.25–1.5 pg/mL).
(3) TNF-α receptor-2 (sTNFα-R2; BioSource Europe,
Nivelles, Belgium: normal range 1–7.8 ng/mL).
Quantitative RT-PCR Analysis in
Abdominal Fat Tissue
Gene expression was assayed in abdominal subcutaneous adipose
tissue obtained from elective surgery (controls) and PD catheter
placement when patients started PD or during PD catheter
exchange. The samples were placed into warm saline, snaps
frozen in liquid nitrogen and stored at −80◦C. For quantitative
RT-PCR analysis frozen tissue samples were lysed in TRI-Reagent
(Ambion, Inc., Austin, TX, United States) using a Polytron
homogenizer to extract total RNA. Complementary DNA was
obtained from 1 µg of RNA by reverse transcription according
to manufacturer’s recommendations using High Capacity RNA
to cDNA kit (Applied Biosystems, Cheshire, United Kingdom)
as described previously (Sandoval et al., 2016). Quantitative PCR
was carried out in a Light Cycler 480 using the FastStart Universal
Probe Master (ROX) (Roche Applied Science) with the following
program: 50◦C, 2 min; 95◦C, 10 min; 60 cycles of 95◦C, 15 s and
60◦C, 10 s; 4◦C; and specific primers sets for human adiponectin,
leptin, TNF-α and glyceraldehyde-3 phosphate dehydrogenase
(GAPDH) mRNAs (Supplementary Table S1) (Ruiz-Carpio
et al., 2017). Data normalized to the housekeeping gene TBP were
analyzed using the 2−11Ct method.
Statistical Analysis
Results are given as the mean ± SD and range. The comparisons
between groups were performed using a non-parametric test, the
Mann–Whitney rank-sum U test. Spearman regression analysis
and “t” student tests were used for paired and non-paired data.
To analyze the statistical differences between the groups, the
ARPr serum curves and the VAS (tables and graphic curves) we
used the variance multi-factor analysis (ANOVA). Figure 4, box
plots show the 25th and 75th percentiles, median, minimum and
maximum values of five independent experiments. The symbols
represent the statistical differences between the groups. In figures,
statistic differences between the groups data were performed
using triple factor ANOVA test and Mann–Whitney rank sum
U test using the SPSS statistic package version 14.5 (Chicago,
IL, United States) and GraphPad Prism version 4.0 (La Jolla,
CA, United States). A “p” value less than 0.05 was considered
statistically significant.
RESULTS
The demographic and basal biochemical characteristics of the
subjects are shown in Table 1. The most relevant findings
were that anorexic patients were older and had significantly
lower levels of nutritional markers and residual renal function
(creatinine clearance). No differences were found in the
frequency of EBD between CAPD vs. automated techniques.
In CAPD group, seven from twelve patients were anorexics,
six obese and eight were asymptomatics. Similarly, there
were no differences in the distribution of EBD by gender.
Six from 12 women were anorexics, seven obese, and nine
were asymptomatics.
Visual Analog Scale (VAS)
The analysis of the VAS applied to the different groups indicated
that the anorexic patients had a lower eating motivation and
obese the higher eating desire (Table 2).
Insulin Resistance Markers
Supplementary Figures S1A–E show the changes in glucose,
insulin, glucagon, C-peptide and GIP after FresubinTM intake.
PD patients showed higher baseline levels of these markers and
“lazy” curves (especially in obese and anorexics) than controls.
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TABLE 1 | Baseline differences between the groups (PD patients).
Parameter Anorexic Obese Asymptomatic Controls P
Age (years) 66.4 ± 10(a,d) 56.3 ± 7.1(b) 49.7 ± 14(a,c) 43 ± 4.7(b,d) (a,b,c,d) < 0.05
DP duration (m) 36.8 ± 32.3 23 ± 11.5 45.5 ± 46.7 NS
CCr (mL/min) 0.5 ± 0.45(a) 1.42 ± 1.01(b) 1.38 ± 1.39(c) 101 ± 7(a,b,c) (a,b,c) < 0.00
nPNA (g/kg/día) 0.87 ± 0.21(a) 1.1 ± 0.25 1.14 ± 0.11(a) (a) < 0.05
KT/V de urea 2 ± 0.25 1.98 ± 0.33 2.17 ± 0.33 NS
Serum Urea (mg/dL) 152 ± 21(a) 159 ± 45(b) 146 ± 51(c) 28 ± 4(a,b,c) (a,b,c) < 0.00
Cr (mg/dL) 10.4 ± 2(a) 11.3 ± 2(b) 10.5 ± 3(c) 1 ± 0.2(a,b,c) (a,b,c) < 0.00
Cholesterol (mg/dL) 174 ± 57.4 211 ± 55.6 188 ± 56 184 ± 30 NS
Albumin (g/dL) 3.7 ± 0.08(a,b) 4 ± 0.2(a) 3.9 ± 0.4 5 ± 0.4(b) (a,b) < 0.05
Transferrin (mg/dL) 209 ± 36 262 ± 47 205 ± 50.7 303 ± 57.2 NS
Prealbumin (mg/dL) 26 ± 7(a,b) 31 ± 2.9(a) 31 ± 7.5 34 ± 3(b) (a,b) < 0.05
RBP (mg/dL) 8.4 ± 3(a,b) 11.5 ± 3(a) 13 ± 2(b) 5.3 ± 1.2 (a,b) < 0.05
IGF-I (ng/mL) 257.5 ± 122(a) 370 ± 142.7(a) 365 ± 224.6 205 ± 91.2 (a) < 0.05
GH (ng/mL) 3.4 ± 3.8 4 ± 4.8 2.2 ± 1.4 1.7 ± 1.7 NS
TSF (cm) 9.5 ± 4(a,b) 24.2 ± 11.4(a) 22.3 ± 9.4(b) 19.9 ± 10.1 (a,b) < 0.05
BSF (cm) 4 ± 0.6(a,b,c) 18.6 ± 7.3(a) 11.4 ± 8.6(b) 13.7 ± 9.5(c) (a,b,c) < 0.05
AMMC (cm) 24.2 ± 1.4(a,b) 27.4 ± 2(a,c) 23.9 ± 13(c) 36.1 ± 13(b) (a,b,c) < 0.05
Diet survey (kcal/day) 1277 ± 467.4(a,b,c) 2320 ± 179.4(a) 2006 ± 351(b) 2089 ± 339(c) (a) < 0.01 (b,c) < 0.05
Fat (kcal/day) 60.4 ± 28.9(a,b) 102 ± 23.2(a,c) 98 ± 22(b) 74.7 ± 15(c) (a,b,c) < 0.05
Proteins (kcal/day) 63 ± 18(a) 85.7 ± 16.6(a) 83.8 ± 13.7 74.5 ± 21.8 (a) < 0.05
Carbohydrate (kcal/day) 98 ± 41(a,b,c) 227 ± 71(a) 155.5 ± 27(b) 248.8 ± 67(c) (a,b,c) < 0.01
BIP. BMI (kg/m2) 23 ± 2(a) 31.1 ± 3(a,b) 25 ± 2 24 ± 1.5(b) (a,b) < 0.05
BIP. Lean (kg) 22.8 ± 3.7(a,b) 30.4 ± 4.5(a) 25.4 ± 2.8 28.6 ± 5.7(b) (a,b) < 0.05
BIP. Fat (kg) 18 ± 5.4(a) 25 ± 8.8(a,b) 13.5 ± 5.3(b) 18.7 ± 4.2 (a,b) < 0.05
IPB. Water (L) 35.7 ± 5.3(a) 43.7 ± 7.7(a) 37.7 ± 5.4 36.6 ± 5.8 (a,b) < 0.05
TNF-α (pg/mL) 121 ± 43.8(a,b,c) 40 ± 11.6(a,c) 38.2 ± 16(b,c) 16 ± 4(c) (a,b) < 0.01 (c) < 0.001
IL-1 (pg/mL) 6.12 ± 0.8(a,b,c) 2.1 ± 0.43(a,c) 2.2 ± 1.34(b,c) 1 ± 0.8(c) (a,b,c) < 0.001
IL-6 (pg/mL) 9.3 ± 3(a,b) 11 ± 5.2(c,d) 5.4 ± 2(a,d) 2 ± 1.2(b,c) (a,b,c) < 0.05 (c) < 0.01
Adiponectin (pg/mL) 29.2 ± 4.2(a) 20.1 ± 7.8(b) 30.3 ± 7.7(c) 9.8 ± 2.4(a,b,c) (a,b,c) < 0.01
HOMA-IR 7.8 ± 1.9(a,b) 10.4 ± 5.1(c,d) 3.5 ± 0.8(a,c) 2.48 ± 0.04(b,c,d) (a) < 0.05 (b,c,d) < 0.01
Letters represent the statistical differences between the groups (read in horizontal). CCr, creatinine clearance. Cr, serum creatinine. RBP, retinol protein binding. IGF-I,
insulin growth factor type I. GH, growth hormone. TSF, tricipital skin fold. BSF, bicipital skin fold. AMMC, arm muscular mean circumference. BIP, bioelectric impedance.
BMI, body mass index. (a–d) Represents the statistical differences between the groups. Statistical comparisons were made group by group (Mann–Whitney U test).
TABLE 2 | Eating motivation measured with VAS in PD patients suffering EBD.
VAS Patients Anorexics (n = 12) Obese (n = 12) Asymptomatics (n = 18) Controls (n = 10) P
Desire to eat before lunch 60 ± 6.1 (a,b) 76.6 ± 6 (a) 67.8 ± 6.9 72.8 ± 3.9 (b) (a,b) < 0.01
Desire to eat after lunch 8.6 ± 2.2 (a) 21.6 ± 4 (a) 13.2 ± 5 13.5 ± 8.5 (a) < 0.05
Hunger before lunch 60 ± 6.1 (a,b,c) 78.3 ± 6 (a) 68.6 ± 4.7 (b) 74.3 ± 4.5 (c) (a) < 0.01 (b,c) < 0.05
Hunger after lunch 8 ± 4.4 (a,b) 21.6 ± 4 (a,c) 12.8 ± 5.5 (c) 17.1 ± 4.8 (b) (a,b,c) < 0.01
Fullness before lunch 28 ± 8.4 (a,b) 18.8 ± 2.5 12.5 ± 4.2 (a) 11.8 ± 4.1 (b) (a,b) < 0.01
Fullness after lunch 81 ± 5.4 (a) 59.1 ± 19.6 (a,b) 77 ± 5.6 (b) 77 ± 5.6 (a) (a,b) < 0.05
Prospective consumption before lunch 59 ± 5.5 (a,b,c) 78.3 ± 4 (a) 71.4 ± 3.7 (b) 75.7 ± 4.5 (c) (a,c) < 0.001 (b) < 0.01
Prospective consumption after lunch 6 ± 2.2 (a,b,c) 25 ± 5.4 (a,b,d) 12.3 ± 2.7 (b,c) 13.5 ± 4.7 (c,d) (a-b) < 0.001 (d) < 0.01
Palatability 60 ± 7 (a,b,c) 75 ± 5.4 (a) 71.4 ± 4.7 (b) 74.3 ± 5.3 (c) (a-c) < 0.01
VAS, Visual Analog Scale is measured in a horizontal scale, maximum value 100. EBD, eating behavior disorder. PD, peritoneal dialysis. Letters represent the statistical
differences (read in horizontal) Mann–Whitney U test.
Anorexigenic Peptide Release
After Food Intake
The anorexic patients had high basal and elevated plasma CCK
levels 30 min after FresubinTM intake (Figure 1A), in parallel
with the peak rise in glucose and insulin (Supplementary
Figures S1A,B). The CCK increment in obese patients was
clearly weaker and retarded. In regard to leptin, obese patients
showed highest values and flat curve. No single group showed
changes in leptin levels (Figure 1B) after food stimulus.
In relation to adiponectin, obese patients had the lowest baseline
levels from PD groups. All groups showed a postprandial
decrease without peaks. On the contrary, the control group
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FIGURE 1 | Continued
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FIGURE 1 | Abnormal anorexigen peptide and pro-inflammatory cytokine release in PD patients with eating behavior disorders. Panel (A) shows the CCK release
after food consumption. Anorexic patients show a very important increase 30 min after FresubinTM intake that fell slightly at 60 and 90 min without reaching the basal
CCK values. This peak explains the poor appetite (VAS) and the early satiety showed by these patients after food intake (Tables 1–3). The remaining groups had flat
curves, except for the controls that maintained the peak values at 30 and 60 min. Obese patients did not show differences along of the curve. P < 0.0001 global
statistical difference between the groups (three factor ANOVA test). Panel (B) shows flat curves of leptin without any modification over time. All PD patients had high
basal leptin plasma levels especially the obese group. P < 0.01 (three factor ANOVA test). Panel (C) shows high adiponectin levels in PD patients, especially in the
anorexic and asymptomatic patients when compared with the controls. All PD groups show a progressive and significant decrease over time and the control
subjects show a peak at 30 min that fell at 90 min. Panel (D) shows the changes in plasma CRF levels after food intake. In normal conditions, CRF levels peak at
30 min and then decrease to values in the normal range after 90 min (controls) p < 0.001 (three factor ANOVA test). However, anorexic patients show an important
elevation at 60 min possibly perpetuating the lack of appetite started by the CCK peak at 30 min (A) and the high basal adiponectin levels (C). P < 0.01 (three factor
ANOVA test). Panel (E) shows the changes in TNF-α plasma levels after standard food intake. Anorexic patients show the highest basal plasma levels and they
increase to nearly 200 pg/mL at 30 min, returning to the basal levels after 90 min. Obese and asymptomatic patients have parallel curves with peaks at 30 min and
returning to basal levels after 60 min. P < 0.01 (three factor ANOVA test). Panel (F) shows the changes in IL-6 and the important peak developed by the anorexics
patients at 30 min that continued to rise slowly to a maximum after 90 min. In the remaining groups IL-6 peaked at 30 min but it decreased at 60 and 90 min. Panel
(G) shows the changes in sTNFα-R2 for which the anorexic patients again had the highest values that decrease after eating, while maintaining the highest values
over the entire time of the curve. However, after its levels fall at 60 and 90 min, they remained constant. Obese and asymptomatic patients and the controls showed
parallel falls. P < 0.001 (three factor ANOVA test).
showed an important peak at 30 min that declined at 60 and
90 min (Figure 1C).
Corticotropin-releasing factor, other ARP that increased after
eating, showed the highest basal levels in obese, with a peak at
30 min and a mild decrease after 90 min. By contrast, the CRF
levels in anorexic patients peaked at 60 min with an important
decrease after 90 min reaching similar values to the remaining
groups (Figure 1D).
Orexigen Peptide Release
After Food Intake
Anorexic patients had lower basal levels of NPY and there was a
significant decrease in NPY 90 min after eating (Figures 2A–C).
The obese patients had higher basal NPY levels and they
experienced a significant increase 30 min after eating and
remaining stable for up to 90 min (Figure 2A).
Postprandial changes in NO3 plasma values were evident
and PD patients showed higher basal levels than the controls
(Figure 2B). All groups showed an important decrease at 30 min
after eating and except in obese patients in whom maximal levels
were evident after 60 min, NO3 levels peaked after 90 min.
In regard to ghrelin, anorexic patients showed a dramatic fall
in ghrelin 30 and 60 min after food consumption (Figure 2C)
in comparison with the remaining groups. All groups showed
similar values of ghrelin at 90 min after food stimulus.
Cytokine Release After Food Stimuli
Anorexic patients had higher basal TNF-α and IL-6 levels with
important “peaks” 30 and 60 min after food consumption that did
not fall after 90 min (Figures 1E,F). The curves from obese and
asymptomatic patients displayed intermediate values between
those of anorexic and control patients. The values for soluble
TNF-α-receptor-2 (sTNFα-R2) were again highest in the anorexic
patients and they decreased after eating albeit these patients
maintained the highest values at all times (Figure 1G).
Glucose Clamp (Euglycemic and
Hyperglycemic)
We found important differences in insulin sensitivity between
PD patients and controls. The obese and anorexic patients
showed higher insulin resistance compared with asymptomatic
and controls (Supplementary Table S2).
Induction of Appetite-Related Peptide
and Cytokine Release Disorders
With Euglycemic Clamp
The constant administration of insulin to maintain stable levels
of glucose in the euglycemic clamp permitted us to evaluate
the influence of exogenous insulin and glucose administration
on ARPr, bypassing the GIT. Both stimuli (glucose and insulin)
were necessary and crucial to induce ARPr reproducing the
abnormal patterns found in anorexic patients (peaks of CCK
and CRF, Figures 3A,C), cytokines (peaks of TNF-α, sTNFα-R2,
and IL-6) after eating in anorexic patients. Importantly, TNF-α
and sTNFα-R2 secretion was consistently higher in anorexic
patients (Figures 3D–F), suggesting that TNF-α was not able to
auto-regulate its fat receptor (sTNFα-R2) and release. Moreover,
in anorexics CCK and CRF maintained their elevated plasma
levels at the end of the curves. Similarly, obese patients showed
NPY peak with orexigenic action which had not declined after
90 min of follow-up (Figure 2D). NO3 and ghrelin showed a
dramatic decline at 60 and 90 min (Figures 2E,F) reproducing
the similar patterns showed in anorexic and obese patients after
food stimulus, except by the last part of the curves.
Relationship Between Cytokines, ARPr,
and Insulin Resistance Marker
Given the known influence of circulating pro-inflammatory
cytokines on insulin-glucose metabolism and their eventual
relation with ARPr, we study their possible association as a
framework. In the whole group, we found a positive linear
correlation between plasma TNF-α levels and IL-1 (0.75,
p< 0.005), as well as between IL-1 and GIP (0.46, p< 0.05), IL-1
and HOMA-IR (0.43, p < 0.05), and TNF-α and HOMA-IR (0.5,
p< 0.05). In obese patients, there was a positive linear correlation
between TNF-α and leptin (0.56, p< 0.05) and there appeared to
be a linear correlation with Ad although this was not statistically
significant (−0.43, p< 0.07, NS). These results suggest that there
may be a feedback that would perpetuate a metabolic framework
that would influence the feeding behavior.
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FIGURE 2 | Abnormal orexigenic peptide release (spontaneous and after euglycemic clamp) in PD patients with eating behavior disorders. All PD patients have
higher NPY plasma levels (the most orexigenic peptide known) than controls (A). P < 0.01 (three factor ANOVA test). In the control group, NPY levels peaked at
30 min followed by a decrease at 60 and 90 min to values below the baseline. Importantly, obese patients show a peak (the highest) at 30 min with a mild fall at
60 min and a rebound at 90 min. The appetite desire shows important correlation with these peaks (Table 2). Asymptomatic and anorexic patients show almost “flat
curves.” With regards NO (represented by NO3), we found important baseline differences between PD patients and controls. After food intake, all patients show an
important fall in plasma NO3 levels at 30 min, except asymptomatic patients that show this fall at 60 min with a rebound at 90 min. Obese patients show an early fall,
rebound at 60 min and a second fall at 90 min. Anorexic patients had a similar curve as the rest but they did not show a second fall (B). P < 0.01 (three factor
ANOVA test). The basal ghrelin plasma levels were higher in obese and lower in anorexic patients and an important fall occurs in all patients that is most pronounced
in the anorexic patients (C). P < 0.01 (three factor ANOVA test). Variance multi-factor analysis (ANOVA). Euglycemic clamp reproduced the abnormalities in
orexigenic peptide release found in PD patients. After glucose and insulin infusion, the change in NPY in obese patients shows an important peak at 30 min that was
maintained during the study (D). P < 0.001 (three factor ANOVA test). Controls and the anorexic patients had lower values than the baseline with a virtually flat curve.
The basal plasma NO3 levels were higher in the PD patients than in the controls, showing a strong fall to reach similar values as in the controls at 30 min (E).
P < 0.01 (three factor ANOVA test). The plasma NO3 levels were very similar between the groups at later times. With regards ghrelin, the obese patients have higher
plasma levels and the anorexic patients the lowest. There was a decrease in NO3 after glucose and insulin infusion that followed a very similar pattern in all groups.
P < 0.01 (three factor ANOVA test). P < 0.01 (three factor ANOVA test). The plasma NO3 levels were very similar between the groups at later times. There was a
decrease in NO3 after glucose and insulin infusion that followed a very similar pattern in all groups. With regards ghrelin (F) the obese patients have higher plasma
levels and the anorexic patients the lowest. P < 0.01 (three factor ANOVA test).
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FIGURE 3 | Euglycemic clamp reproduced the abnormalities in anorexigenic peptide pro-and inflammatory cytokine release found in PD patients. A euglycemic
clamp permits us to evaluate the effect of insulin and exogenous glucose administration on ARPr, by-passing the gastrointestinal tract. The hyperglycemia and
hyperinsulinemia induced are sufficient to abnormally release CCK (A). P < 0.001 (three factor ANOVA test). Anorexic patients maintain their CCK peak when
compared with the remaining groups. With regards adiponectin, PD patients had higher plasma levels when comparison to the controls (B). P < 0.001 (three factor
ANOVA test). The obese patients show lower values than the anorexic and asymptomatic patients. All PD patients showed an important fall between 30 and 90 min.
By contrast, controls had elevated levels that peaked at 30 min and then fell at 60 and 90 min. Another important anorexigen substance, CRF, also shows important
changes and in anorexic patients high levels were reached at 60 min that were maintained until 90 min. The remaining groups show intermediate peaks (C).
P < 0.01 (three factor ANOVA test). The changes TNF-α, IL-6, and sTNFα-R2 after glucose and insulin infusion are shown in (D–F). Euglycemic clamp reproduced
the different curves from anorexic, obese and asymptomatic patients and controls found after eating. However, the ends of the curves (60 and 90 min) were flat,
possibly due to the stable and high insulin and glucose levels maintained by the euglycemic clamp. P < 0.001 (three factor ANOVA test).
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The Relationship Between ARPr and
Cytokines May Promote Uremic Anorexia
In anorexic patients, there was a positive linear correlation
between basal IL-1 and CCK (0.45, p < 0.05), while TNF-α
showed a negative correlation with ghrelin (−0.66, p < 0.01).
Similarly, NPY showed a negative linear correlation with basal
IL-1 (−0.52, p < 0.05) and TNF-α (−0.51, p < 0.05), and a
positive relationship with CRF (0.51, p < 0.01). Finally, basal
leptin levels were negatively correlated with ghrelin (−0.54,
p < 0.01). After food consumption, NPY was negatively
correlated with basal IL-1 after 30 and 90 min (−0.64, p < 0.01
and−0.61, p< 0.01, respectively).
The Relationship Between ARPr and
Insulin Resistance May Promote High
Food Intake in Obese Patients
In this group, we found a positive linear correlation between basal
serum leptin and basal BMI (0.6, p< 0.01), fat mass (by BIA: 0.67,
p < 0.01), NO3 (0.51, p < 0.05), HOMA-IR (0.66, p < 0.01), and
Ad (−0.54, p < 0.01). Likewise, NPY was positively correlated
with ghrelin (0.45, p < 0.05). After food stimuli, the NPY levels
after 90 min showed a positive linear relationship with all points
of the leptin curve at baseline, 30, 60, 90 min, (0.51, p< 0.05; 0.67,
p< 0.01; 0.67, p< 0.01; 0.63, p< 0.01, respectively).
Relationship Between ARPr, Cytokine,
and Appetite Desire (VAS)
Appetite desire was positively correlated with NPY and negatively
correlated with CCK (basal and post-stimuli, Figures 2A and 1A,
respectively, Tables 3, 4) and TNF-α in the whole group,
suggesting a cause–effect relationship between these molecules
and VAS. In anorexic patients TNF-α and CCK showed an
inverse correlation with appetite desire, especially 30 min after
eating (Table 3). TNF-α was associated with the sensation of
fullness and poor palatability, as well as to poor prospective
food consumption 90 min later. In obese patients NPY showed
the strongest relationship with VAS, especially 30 min after
food intake, and it was associated with high palatability and
a stronger desire for prospective consumption 90 min after
eating (Table 3).
Appetite-Related Gene Expression in
Abdominal Fat Tissue
The TNF-α gene was over-expressed in all uremic patients, and
anorexic patients showed higher mRNA expression than other
groups (Figure 4A). Importantly, TNF-α gene expression was
positively correlated with TNF-α plasma levels (0.66, p < 0.05).
Obese patients had the lowest fat leptin expression, which
was negatively correlated with plasma leptin levels (−0.54,
p < 0.0.5), indicating a negative feedback that down-regulated
the expression of this gene (Figure 4B). All patients showed lower
global Ad fat expression than controls, and the lowest expression
was evident in obese patients (Figure 4C).
Relationship Between Fat
Appetite-Related Gene Expression and
Insulin Resistance
There was a positive linear correlation between plasma insulin
(Supplementary Figure S1B) and fat TNF-α expression (0.55,
p < 0.01), as well as a negative relationship between plasma
insulin and fat leptin expression (0.34, p < 0.05) or fat
Ad expression (0.44, p < 0.05) (Figures 4A–C). Similarly,
HOMA was positively related with fat TNF-α expression
(0.64, p < 0.01) and it was negatively related to fat leptin
expression (0.5, p< 0.01).
Relationship Between Fat
Appetite-Related Gene Expression
and Appetite Desire (VAS)
Table 5 shows the relationships between TNF-α, leptin and Ad
gene expression, and appetite, measured by VAS, in anorexic and
obese patients. The participation of TNF-α and its association
with VAS was predominant in anorexic patients.
TABLE 3 | Relationship between anorexigens/orexigens and VAS in anorexics PD patients.
CCK- CCK- CCK- CCK- NPY- NPY- NPY- NPY-
VAS Peptides (#) 0 min 30 min 60 min 90 min 0 min 30 min 60 min 90 min TNF-α&
Desire to eat before lunch −0.34∗ −0.6∗∗ −0.52∗∗ −0.4∗ 0.36∗ 0.33∗ 0.38∗ −0.56∗∗
Desire to eat after lunch −0.43∗ 0.46∗ 0.4∗
Hunger before lunch −0.41∗ −0.66∗∗ −0.47∗ −0.5∗∗ 0.34∗ −0.66∗∗
Hunger after lunch −0.55∗∗ −0.52∗∗ −0.53∗∗
Fullness after lunch 0.55∗∗ −0.46∗ −0.6∗∗ 0.51∗∗ 0.52∗∗
Prospective consumption before lunch −0.48∗ 0.48∗ 0.34∗ 0.47∗ −0.48∗
Prospective consumption after lunch −0.4∗ 0.56∗∗
Palatability −0.5∗ −0.53∗∗ −0.75∗∗ 0.42∗ 0.42∗ −0.6∗∗
Hunger 2 h before lunch −0.38∗ −0.4∗ −0.6∗∗ 0.34∗ −0.5∗∗
Satiety 2 h after lunch 0.53∗∗ 0.42∗
VAS, Visual Analog Scale. PD, peritoneal dialysis. #, means the time after the food stimulus; &, baseline. ∗p < 0.05, ∗∗p < 0.01.
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TABLE 4 | Relationship between anorexigens/orexigens and VAS in obese PD patients.
CCK- CCK- CCK- CCK- NPY- NPY- NPY- NPY-
VAS Peptides (#) 0 min 30 min 60 min 90 min 0 min 30 min 60 min 90 min TNF-α&
Desire to eat before lunch −0.41∗∗ −0.38∗ 0.5∗∗ 0.58∗∗ 0.4∗
Desire to eat after lunch −0.38∗ −0.38∗ −0.48∗ 0.54∗∗
Hunger before lunch −0.5∗ −0.36∗ −0.58∗∗ −0.35∗ 0.4∗ 0.38∗ 0.55∗∗ −0.31∗
Hunger after lunch −0.38∗ −0.39∗ −0.33∗ 0.33∗ 0.54∗∗ 0.5∗∗
Fullness after lunch 0.43∗ −0.34∗ −0.34∗
Prospective consumption before lunch 0.57∗∗ 0.6∗∗ 0.37∗ 0.53∗∗ −0.33∗
Prospective consumption after lunch −0.37∗ 0.53∗∗ 0.51∗ 0.53∗∗
Palatability −0.46∗ −0.56∗∗ 0.41∗ 0.63∗∗ −0.37∗
Hunger 2 h before lunch −0.35∗ 0.51∗∗ 0.56∗∗ 0.7∗∗
Satiety 2 h after lunch 0.35∗ −0.44∗
VAS, Visual Analog Scale. #, means the time after the food stimulus; &, baseline. Linear correlations: ∗p < 0.05, ∗∗p < 0.01.
FIGURE 4 | Expression of genes related to eating behavior disorders in PD patients in abdominal subcutaneous fat (qPCR). PD patients show higher fat tissue TNF-α
expression than controls. The highest TNF-α expression was in the anorexic patients, with obese and asymptomatic patients showing intermediate expression. The
high TNF-α plasma levels present in anorexic patients did not inhibit the TNF-α expression in fat suggesting that in uremia, fat tissue is an important source of
pro-inflammatory cytokines (A). With regards leptin expression in fat tissue, the obese patients show an important downregulation of leptin gene expression in fat
when compared to the remaining groups. This down expression may be associated with a negative feedback loop induced by the high plasma TNF-α levels.
Anorexic and asymptomatic patients express intermediate levels of leptin between obese patients and controls (B). Panel (C) shows the adiponectin expression,
which was lower in the fat from PD patients than in controls. As expected, obese patients expressed adiponectin the weakest and again, anorexic and asymptomatic
patients had expression levels intermediate to those of obese patients and controls. Box plots show the 25th and 75th percentiles, median, minimum and maximum
values of five independent experiments. The symbols represent the statistical differences between the groups (ANOVA one-way and Mann–Whitney rank sum U test).
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DISCUSSION
There are three important findings arising from this study:
(1) We have identified well-defined patterns of EBD in
dialysis patients, defined by the VAS and nutritional
markers (Table 1 and Supplementary Table S2).
(2) The presence of ARPr disorders associated with
insulin resistance and systemic inflammation
(Tables 3, 4 and Figures 1–4).
(3) The close relationship between EBD, abnormal ARP,
and cytokines release (Tables 3, 4) and cytokines fat-
tissue gene expression (Table 5 and Figure 4).
Characterization of Appetite
Disorders in PD Patients
Visual Analog Scale has been used to measure eating motivation
and validated in PD, HD, and kidney transplant patients
(Hylander et al., 1997). Employing this scale, we demonstrate
that patients suffering anorexia showed the minimal score of
hunger, lower palatability and eating desire, in conjunction with a
sensation of greater fullness, contrasting with the features found
in obese patients. Importantly, our patients showed a dietary
preference for carbohydrates.
Uremic Insulin Resistance
As it has been demonstrated by others (Zoccali et al., 2005; Kalra
et al., 2008), we found different grades of insulin resistance in our
PD patients that were related with different EBD.
Baseline Results
Our PD patients showed high spontaneous baseline plasma levels
of anorexigenic peptides and cytokines, including C-peptide and
GIP, which have an anorexigenic effect mediated by insulin-
glucose metabolism. Importantly, anorexic patients have the
highest plasma levels of anorexigens including TNF-α and low
NPY levels (orexigen), as we previously described (Aguilera et al.,
1998, 2001). IL-1 and IL-6 are another cytokines associated with
loss of appetite (McCarthy et al., 1995). According to our results,
patients with anorexia have the lowest RRF and the highest
cytokine concentration, suggesting that RRF is a more important
determinant of appetite through this via than dialysis dose.
Results Following Food Intake
We clearly identified distinct alterations in ARPr pattern in
studied groups after food intake. Given these results, we explored
the influence of exogenous insulin and glucose administration,
together or separately (hyperglycemic and euglycemic clamp),
on ARP and cytokine release bypassing the GIT.
Anorexigen Substances
Cholecystokinin is a potent anorexigen with peripheral and
central actions that is implicated in the pathogenesis of anorexia
nervosa, cancer, senile and alcoholic anorexia (Dupré et al., 1973).
In PD patients with anorexia, the plasma levels of CCK were
elevated after eating. CCK is also retained in dialysis patients and
it is not modified by PD or HD (Peikin, 1989). Previously, we
did not find high CCK plasma levels in anorexic patients prior to
food stimulus (Aguilera et al., 1998). Here, we identified a “peak”
of plasma CCK 30 min after eating (Figure 1A), which may be
responsible for the early sensation of fullness. This CCK “peak”
was also found in patients with anorexia nervosa and although
the exact cause is unknown, this phenomenon is potentially
reversible when the nutritional status is recovered (Owyang
et al., 1979). Modifications to peripheral insulin activity when
nutrition or systemic inflammation improves might explain this
phenomenon. By contrast, obese patients showed a delayed CCK
“peak” and a similar abnormality may be found in non-uremic
patients with bulimia nervosa, where the CCK “peak” is delayed
and is 50% lower than those in control (Harty et al., 1991).
Again, the positive linear correlations found between CCK and
IL-1, IL-1, and GIP, and GIP and insulin (other anorexigen) may
perpetuate the anorexia and the insulin resistance suffered by our
patients (Daun and McCarthy, 1993). In fact, a synergic effect
between IL-1 and CCK inducing anorexia has been described,
while IL-1 and GIP are factors that stimulate insulin release
by the pancreas (Geracioti and Liddler, 1988). The euglycemic
clamp replayed the same CCK and cytokines release patters
(Figures 3A,D–F). These results suggest that insulin metabolism
TABLE 5 | Relationship between fat gene expression and appetite desire (VAS).
Anorexics Obese patients
VAS/gene expression TNF-α Leptin Adiponectin TNF-α Leptin Adiponectin
Desire to eat before lunch −0.66∗∗ −0.55∗∗ −0.54∗∗ 0.37∗
Desire to eat after lunch −0.43∗ 0.45∗
Hunger before lunch −0.4∗ −0.55∗ −0.34∗ −0.4∗
Hunger after lunch
Fullness after lunch 0.7∗∗ 0.37∗
Prospective consumption before lunch −0.6∗∗ 0.56∗∗
Prospective consumption after lunch −0.46∗ −0.37∗ −0.5∗
Palatability −0.5∗∗
Hunger 2 h before lunch −0.41∗ −0.35∗ 0.44∗
Satiety 2 h after lunch 0.5∗
VAS, Visual Analog Scale. Linear correlations: ∗p < 0.05, ∗∗p < 0.01.
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and high grade of systemic inflammation may be key in the
induction of anorexia in PD patients.
Leptin is an adipose tissue hormone that modulates appetite
and insulin activity in target cells, inducing insulin resistance
(Klein et al., 1996). Although, we did not find changes in leptin
levels, in non-renal population plasma leptin appears to increase
4 h after food intake (Klein et al., 1996). Unfortunately, we have
no data from this time interval.
Adiponectin, in sharp contrast to leptin, plasma Ad levels are
negatively correlated with body fat, decreasing with obesity and
increasing with weight loss (Liu et al., 2003; Coll et al., 2007).
Moreover, hyperadiponectinemia can reduce the food intake in
rats (Coope et al., 2008). Here, we found high plasma Ad levels in
PD patients, although, the lowest values were registered in obese
patients as described elsewhere in non-renal obese (Coll et al.,
2007). In normal conditions, Ad levels increase 30 min after food
intake and decrease over the following 60 and 90 min. In all our
patients the decrease was delayed, the obese patients maintaining
the lowest values. It is generally accepted that Ad is negatively
related to insulin levels due to its anti-insulin resistance effects
(Isganaitis and Lustig, 2005). However, in uremia, the negative
feedback between insulin secretion and Ad may be partially
broken since adiponectin is retained (Díez et al., 2005). Indeed,
the exogenous administration of insulin and glucose in the
euglycemic clamp strongly regulated Ad in all studied groups
(Figure 3B). Therefore, the differences in Ad release in these
patients appear to be mediated by insulin resistance contributing
indirectly to EBD in PD patients.
Corticotropin-releasing factor is produced by hypothalamic
neurons that exert a central and peripheral anorexigenic effect,
inhibiting that of NPY (Kalra et al., 2008). While there were
no basal differences between PD patients, 60 min after eating
anorexic patients displayed an important peak of CRF that
was correlated with VAS. In addition to insulin, one of the
most important regulators of CRF activity is plasma cortisol,
therefore impaired cortisol suppression may explain EBD in
uremia (Deshmukh et al., 2005). Unfortunately, we did not
study the circadian variations in plasma cortisol and ACTH. In
accordance with our findings, an important disruption in insulin
release that may be associated to disorders in CRF secretion and
vice-versa has already been observed in patients suffering chronic
renal failure (Feneberg et al., 2002). Again euglycemic clamp
reproduced the CRF release patters in all groups suggesting a
deep dependence of insulin and glucose levels (Figure 3C).
Orexigenic Substances
In normal condition a “peak” of NPY appeared 15–30 min after
food intake and may be responsible for hunger persistence,
possibly augmenting the sensation of gastric emptiness
(Weisman et al., 1998). This explains the popular idea that small
snacks before the main meal stimulate appetite. Importantly,
this NPY “peak” was absent in our patients with uremic
anorexia (Figure 2A), who conversely showed a significant
decrease in NPY 90 min after eating that fell below the basal
values, explaining the early and late lack of appetite seen in
anorexics. NPY “peaks” were evident 30 and 90 min after
eating in obese patients, which could explain the repetitive
and greater amount of food ingested. This post-prandial NPY
“peak” rebound at 90 min has been described previously in
bulimic patients (Rosenbaum et al., 1997). Moreover, our obese
group showed relatively high NPY levels, although within the
normal range, which could be associated with high appetite
desire. Recent studies suggest the existence of disorders in
hunger-hypothalamic receptor sensibility in the non-uremic
obese population (Rosenbaum et al., 1997; Weisman et al., 1998).
NPY and leptin levels are significantly higher in Zuker (Ob/Ob)
rats, inducing repetitive and compulsive food intake due to the
failure of leptin to inhibit NPY release (Stricker-Krongrad et al.,
1994). In uremic status, hypothalamic receptor disorders have
been poorly studied, although the parallels in the glucose, insulin
and NPY curves and their complex relationship may underlie the
excessive and sustained NPY release. Obesity and uremia status
may be the maximal expression of this disorder since both are
associated with the hyperinsulinemia and insulin resistance that
might perpetuate the abnormal NPY release. The euglycemic
clamp results support the role of insulin metabolism on NPY
release (Figure 2D).
But not only carbohydrate intolerance appears to affect
appetite in uremia. Cytokines also may be affected by insulin
metabolism. We recently demonstrated an inverse relationship
between TNF-α and NPY in PD patients, and we speculated that
TNF-α may inhibit its orexigenic effect (Xu et al., 1988; Aguilera
et al., 1998). We also found a negative linear correlation between
NPY and IL-1, supporting the MIA hypothesis (Aguilera et al.,
1998). Together, ARPr, TNF-α, IL-6, and s-TNFα-R2 showed
important modifications after food stimulus. This parallelism
invites to think that pro-inflammatory cytokines may synergize
and perpetuate EBD as anorexia in our patients.
Nitric oxide is another important appetite stimulator (Xu
et al., 1988; Vallance et al., 1992; Squadrito et al., 1994)
and experimentally, a decrease in NO production inhibits
appetite (Squadrito et al., 1994). A potent NO-synthase inhibitor
accumulated in uremic patients (Vallance et al., 1992) and as a
consequence, one might expect dialysis patients to have lower
plasma NO3 values than controls. However, it did not occur.
This apparent contradiction may be explained by the uremic
retention of inactive forms of NO, represented by NO3, by
the NO relationship with the pool of arginine (its substrate),
ornithine, pro-inflammatory cytokines capable of inhibiting NO
synthase, endothelin-1 and insulin metabolism (Yan et al., 2008).
NO stimulates the insulin release and the equilibrium between
NO and endothelin-1 with a predominium of endothelin-1
inducing insulin resistance (Yan et al., 2008). Moreover, high
plasma levels of endothelin-1 have been reported in uremics
(Roccatello et al., 1997).
On the other hand, modification of NO after food intake and
after the euglycemic clamp highlights the role of insulin and
uremic insulin resistance on hunger-satiety control (Figure 2E).
Moreover, the high TNF-α plasma levels shown by anorexic
patients may explain the dramatic fall in NO3 after food stimuli
due to decreased NO synthesis perpetuating the early anorexia
(Yan et al., 2008).
Ghrelin is another orexigen GIT hormone that is secreted
in response to stomach empty. It decreases after food intake,
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constituting a peripheral negative feedback and increase
after weight loss, in fasting condition and insulin induced
hypoglycemia (Theander-Carrillo et al., 2006). Ghrelin plasma
levels in uremia are generally elevated, although anorexic
patients show relatively lower values (Aguilera et al., 2004a).
We confirmed our previous findings, that PD patients maintain
higher ghrelin plasma levels than controls (Figure 2C). Moreover,
we confirmed the strong inverse relationship between ghrelin
levels and glucose or insulin release after food intake, and that
after euglycemic clamping ghrelin maintained its levels in parallel
with the insulin and glucose levels (Figure 2F).
Not only insulin resistance and inflammation participate in
appetite regulation, but the expression of genes in abdominal fat
associated with insulin metabolism can also regulate appetite. Fat
TNF-α over-expression (Figure 4A) is not inhibited by its high
plasma levels and in fact, the levels of sTNFα-R2 are maintained,
indicating that fat tissue is an important source of pro-
inflammatory cytokines in uremia. By contrast, obese subjects
have the lowest leptin and Ad fat expression (Figures 4B,C)
indicating their down-regulation in fat, possibly due to negative
feedback through their high plasma, as described by elsewhere
(Nordfors et al., 1998).
Our results permit to explain the different eating behaviors in
PD patients according to different degrees of insulin resistance
and systemic inflammation. The euglycemic clamp exactly
reproduces the insulin sensitivity and abnormal ARP and
cytokines release patterns in anorexics and obese, indicating
that glucose-insulin metabolism definitely triggers these
appetite disorders.
Finally, other abnormalities as sex hormones, brain neuro-
transmitters or receptors acquired disorders in uremia (i.e.,
MC4-r), may contribute to the diversity of EBD in this population
(Xu et al., 1988; Cheung et al., 2005; Carrero et al., 2008).
CONCLUSION
In PD patients, EBD are modulated by an abnormal baseline
levels of ARP and cytokines, which are abnormally released after
food intake and highly dependent of insulin metabolism. The
renal ARP retention, the excess of pro-inflammatory cytokines
and uremic carbohydrate intolerance, with predominance of
inflammation in anorexics or hyperinsulinemia in obese patients,
may explain the tendency to develop one or other EBD.
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FIGURE S1 | Insulin resistance markers release in PD patients with eating
behavior disorders. Panel (A) shows the glucose release after standard food
intake (FresubinTM). PD patients, especially obese patients, show an important
and sustained elevation of glucose that reaches values between 150 and
165 mg/dL. In the control group glucose peaks at 30 min, decreasing to normal
values at 60 min and then declining at later periods (90 min). P < 0.001 (three
factor ANOVA test). Panel (B) shows a similar pattern of insulin release as glucose.
In obese the insulin curve was highest and maintained around 150 µU/mL a long
the time (90 min). All PD patients showed “lazy curves” with insulin levels between
50 and 90 µU/mL, whereas controls show a final decrease in insulin at 90 min.
P < 0.001 (three factor ANOVA test). Panel (C) shows the glucagon plasma levels
in the different groups. Controls show a mild elevation at 60 min with a significant
decrease at 90 min. In PD patients the levels remain constant (“flat curves”) except
for the peak detected in obese patients at 30 min. P < 0.01 (three factor ANOVA
test). Panel (D) shows the C-peptide curves and again, obese patients have the
highest values in the curve. The controls show a peak at 60 min with a significant
decrease at 90 min. P < 0.001 (three factor ANOVA test). Panel (E) shows the GIP
levels in the groups studied. PD patients display an important elevation at 30 and
60 min (anorexics) with no decrease at later periods, whereas the lowest values
were in the controls maintaining the peak at 60 and 90 min. Obese patients
showed an important and sustained elevation of glucose that reaches values of
150–165 mg/dL. Control group showed a glucose peaks at 30 min, decreasing to
normal values at 60 min and then declining at 90 min. In whole PD patients, a
similar pattern of insulin release and glucose was found “lazy curves.” Obese
showed the highest insulin values with fat curves at later periods, whereas
controls show a final decline in insulin curve at 90 min. In regard to glucagon,
patients showed elevated baseline levels than controls, especially in obese and
anorexics with a small peak at 30 and 60 min, respectively. Controls show a mild
elevation at 60 min with a significant decrease at 90 min. The C-peptide a
pancreatic insulin reserve marker, showed the highest values in obese. Controls
show a peak at 60 min with a significant decrease at 90 min. Figure 1E shows
the changes in GIP levels after food stimulus. Anorexic PD patients display an
important elevation of GIP at 30 and 60 min which is maintained at later periods,
whereas controls showed lowest values with peak at 60 and decreasing at
90 min. P < 0.01 (three factor ANOVA test).
TABLE S1 | Gene primers.
TABLE S2 | Euglycemic (insulin sensitivity) and hyperglycemic clamp study
(insulin secretion).
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